Caplin Point Laboratories Ltd
CAPLIPOINTCaplin Point Laboratories Ltd is strength at full price. The numbers are improving — and a P/E at the 83rd percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 83rd percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (14 weeks in) while the P/E sits at the 83rd percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +18.5% year on year, and 77% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Caplin Point Laboratories Ltd trades at ₹2,755, in a confirmed uptrend and 14 weeks into that stage. That is +24.2% against its own 200-day average. It sits at 96% of a 52-week range of ₹1,558 to ₹2,811. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 25 straight weeks.
Today the stock is in a confirmed uptrend — week 14 of stage 2, confirmed. At ₹2,755 it trades +24.2% versus its 200-day average and sits at 96% of its 52-week range (₹1,558–₹2,811).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +1,242% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 25 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Caplin Point Laboratories Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: Not stated in the research file. Our fortnightly research layers last read it on 22 August 2026.
Our read, 22 August 2026. A LATAM-pharma and US-sterile compounder building regulated-market scale from its own balance sheet — earnings growing steadily while the sterile injectable ramp is the next PAT multiplier.
From the numbers. Caplin Point is in mid-expansion of a multi-year earnings compounding cycle, but the valuation has moved well ahead of the cycle trough. The PE at 30.1x sits at the 79th percentile of its 10-year range. The stock has…
From the price. Price stage 2, week 14 — above its 200-day line, relative strength rising.
From the research. A LATAM-pharma and US-sterile compounder building regulated-market scale from its own balance sheet — earnings growing steadily while the sterile injectable ramp is the next PAT multiplier.
🚨 Where they disagree. Caplin Point is in mid-expansion of a multi-year earnings compounding cycle, but the valuation has moved well ahead of the cycle trough. The PE at 30.1x sits at the 79th percentile of its 10-year range. The stock has run 4.3x over 36-48 months and is within 2% of its peak. This is a quality compounder at a full price, not a depressed-breakout setup.
What is proven. A LATAM-pharma and US-sterile compounder building regulated-market scale from its own balance sheet — earnings growing steadily while the sterile injectable ramp is the next PAT multiplier.
What is not proven yet. CSL quarterly revenue growth falling below 15% year-on-year for two consecutive quarters while the price-to-earnings ratio stays above 27x — that combination signals the sterile ramp is not monetising as the market expects, creating a compression trap where the growth premium deflates before earnings grow into it.
🚨 What would change our mind. CSL quarterly revenue growth falling below 15% year-on-year for two consecutive quarters while the price-to-earnings ratio stays above 27x — that combination signals the sterile ramp is not monetising as the market expects, creating a compression trap where the growth premium deflates before earnings grow into it.
Layer 1 read, 22 August 2026 — KEEP. Profit is real and compounding, but the price is top-of-decade and the capacity promise moved a fourth time. The business is genuinely working: sales and profit per share rose in every one of the last twelve quarters while the profit margin held at 34-35%, and the American sterile-injectables arm nearly tripled its own-brand sales from 14.4 to 43.1 crore in a single year. I cleared the biggest suspicion hanging over it — the flag that said profit was really investment income — because the 34 crore a quarter is simply bank interest on a 2,875-crore cash hoard that keeps growing, not a one-off windfall, and the company still spent under 200 crore on actual plant while generating 523 crore of operating cash. The problem is price and promises: the shares change hands at the 79th percentile of their…
What would change Layer 1’s mind. Sharpening the Timeline's own kill-switch: US sterile quarterly revenue growing below 15% year-on-year for two consecutive quarters while the shares still trade above 27 times earnings — because that is the exact combination where the growth premium deflates before profit can grow into it. I add one of my own from the driver I lean on: if operating expenses stop falling as a share of revenue and the rest-of-world profit margin drops below 30% for two quarters running, the operating-leverage leg…
Layer 2 read, 22 August 2026 — BENCH. The earnings are real, but both the stock and its sector are too mature for a fresh advance. US sterile revenue nearly tripled year on year, matching the sector's broad export-recovery claim. The brake is timing: the stock has already risen 4.3 times and sits 2% below its peak, while the sector is TOPPING with high modelled margins and valuation.
What would change Layer 2’s mind. Advance it only if the price and sector valuation reset materially while US sterile growth stays above 15% year on year; drop it if that growth stays below 15% for two quarters while PE remains above 27x.
What the company does. Caplin Point has grown PAT from 251 crore in FY21 to 650 crore in FY26 with zero debt, funding a 1,000 crore capex cycle from operating cash. The US sterile business nearly tripled its own-label revenue year-on-year in Q1 FY27, proving the ramp is real. The stock trades at the upper end of its historical valuation range, so the thesis depends on delivery, not re-rating.
Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Caplin Point Laboratories Ltd reported ₹610 Cr of revenue in the Jun 26 quarter, +19.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 24.8% a year. The last full year, FY26, came in at ₹2,187 Cr. The last four reported quarters add to ₹2,287 Cr.
Why this happened. CSL own-label revenue grew from 14.4 crore to 43.1 crore year-on-year in Q1 FY27, tracking ahead of the 200-crore FY27 full-year target. The US business grew 26% overall. CSL holds 39 of 60-plus approved ANDAs and has 40-plus products in pipeline spanning pre-filled syringes, ophthalmic suspensions and other sterile forms. New lines are commissioning over the next 6-18 months, each unlocking additional ANDA commercial capacity.
FY26 revenue came in at ₹2,187 Cr (+12.9% on the year), capping 10 years at 24.8% compound. The latest quarter (Jun 26) printed ₹610 Cr, +19.6% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +15.0% growth against the decade's 24.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +15.0% over the last 4 quarters against +14.1%/yr over the last 8 — stabilising; TTM profit +19.6% vs +18.6%/yr — stabilising.
FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported.
FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Caplin Point Laboratories Ltd's operating margin is 35.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 21.0% to 36.0%. The current quarter sits inside that band.
Why this happened. OPM has run at 34-35% for six consecutive quarters without dipping below 33%. In Q1 FY27, the EBITDA margin expanded as the operating-expense ratio fell from 25.7% to 23.6% despite gross margin moving with mix. Personnel costs from the hiring phase are already embedded; each incremental revenue rupee contributes at a high marginal rate.
The latest quarter's operating margin is 35.0%, +0.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 21.0%–36.0%.
Why the margin moved: operating margin went +0.1 pp year on year while gross margin went −1.9 pp — the gain came mostly from the gross line: input costs and pricing.
FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported.
FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Caplin Point Laboratories Ltd earned ₹179 Cr of net profit in the Jun 26 quarter, +18.5% year on year. It is the 12th consecutive quarter of growth. Full-year FY26 profit was ₹650 Cr. The 10-year compound rate is 30.3%. That is 29.3% of the quarter's revenue. The same quarter a year earlier earned ₹151 Cr.
Jun 26 profit was ₹179 Cr, +18.5% year on year — the 12th consecutive quarter of growth. On the full year, FY26 printed ₹650 Cr (+20.1%), and the 10-year compound rate is 30.3%.
Why profit moved: revenue contributed +19.6% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +19.6% vs revenue +15.0%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
FY26-Q4. revenue ₹600 Cr and profit ₹173 Cr as reported.
FY27-Q1. revenue ₹610 Cr and profit ₹179 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 77% of Caplin Point Laboratories Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹523 Cr of operating cash against ₹650 Cr of profit. After ₹197 Cr of capital spending, ₹326 Cr was left as free cash.
FY26: operating cash of ₹523 Cr against reported profit of ₹650 Cr, leaving free cash of ₹326 Cr after ₹197 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 77% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 77%: the cash cycle stretched 28 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: conversion is below par and the cash cycle has stretched 28 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Caplin Point Laboratories Ltd's cash conversion cycle runs 194 days in FY26, up from 166 days in FY21. Capital spending ran ₹505 Cr over the last 3 years. At FY26 sales of ₹2,187 Cr each day of that cycle holds about ₹6.0 Cr, so roughly ₹1,162 Cr sits inside the business at any moment.
Why this happened. Chile entered with 135 product registrations and 10 million dollars of orders secured for 18 months. Mexico swept all 8 products in a 2-year government tender, holds 25 registrations, and has a 4 million dollar near-term sales target; local manufacturing is under evaluation. The El Salvador supplementary tender is pending decision and could add 10-15% of the original tender volume.
FY26: debtors at 138 days, inventory at 181 days — roughly 6.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 194 days, looser than FY21's 166.
The full loop: cash goes out to suppliers and production on day 0; stock waits 181 days to sell; customers pay about 138 days after that; and suppliers themselves are paid at 125 days — netting out to the 194-day cycle.
In money terms: at FY26 sales of ₹2,187 Cr, each day of the cycle holds about ₹6.0 Cr — so the 194-day loop keeps roughly ₹1,162 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹505 Cr over the last 3 fiscal years against ₹192 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹234 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Caplin Point Laboratories Ltd earns a ROCE of 24% in FY26. Return on invested capital clears the cost of that capital by +9.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 29.7% net margin on 0.54× asset turns.
FY26 ROCE is 24%.
Why the return is what it is — the wiring (FY26): 29.7% net margin × 0.54× asset turns × 1.20× balance-sheet leverage ≈ 19.2% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 21.6% − 12.0% = a +9.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Caplin Point Laboratories Ltd carries total debt of ₹5.0 Cr against shareholder equity of ₹3,631 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Why this happened. The company holds 1,503 crore in cash and cash equivalents plus 2,875 crore total liquid assets against zero bank debt. Residual capex of approximately 510 crore is fully funded. A Mexico distribution acquisition and the Amaris Clinical expansion are both internally funded options that could accelerate the thesis without dilution.
Mar 26: total debt of ₹5.0 Cr against shareholder equity of ₹3,631 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 2.4 points of Caplin Point Laboratories Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 5.8% of the company. Domestic institutions moved +1.0 points over the same window, to 2.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +2.4 points over 8 quarters to 5.8%; Domestic institutions: +1.0 points over 8 quarters to 2.5%; Promoters: +0.0 points over 8 quarters to 70.6%.
Why the register moved: foreign institutions drove it (+2.4 points), alongside domestic institutions (+1.0 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Caplin Point Laboratories Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Caplin Point Laboratories Ltd trades at 31.5× P/E, at the pricey end of its own range (83rd percentile). Its long-run median P/E is 22.4×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 31.5× is at the pricey end of its own range (83rd percentile), against a long-run median of 22.4× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +19.6% against a +22.7% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +24.2%/yr price move, ~+20.7%/yr came from earnings growth and ~+3.5 pp from the multiple (expanding); over 10y, of the +26.5%/yr price move, ~+26.8%/yr came from earnings growth and ~−0.3 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 24 August 2026 price, Caplin Point Laboratories Ltd was paying for profit growth of about 16.6% a year. Profit itself has compounded 30.3% a year over the past 10 years. Today the market pays 31.5× P/E, the 83rd percentile of its own 11-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 24 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Caplin Point Laboratories Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 24.4% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +12.9% | +14.2% | +15.6% | +24.8% |
| Profit | +20.1% | +19.9% | +21.0% | +30.3% |
| EPS | +19.6% | +19.4% | +21.4% | +30.1% |
| Share price | +22.7% | +37.3% | +24.2% | +26.5% |
4-Factor Sector Score
61.8/100 — rank 10 of 44 in Pharma - Formulators · 100% evidence confidence
Caplin Point Laboratories Ltd scores 61.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 10. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 19 + 17.7 + 9.4 + 15.7 = 61.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Caplin Point Laboratories Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Sterile Capacity Timeline Extended · 12 August 2026. The November 2025 and February 2026 calls presented 12 to 15 injectable lines as coming online within the next two years. In the August 2026 call, management said only 13 lines had visibility and that the final three to four lines could be activated in 2029 and beyond, materially extending the previously indicated timeline without explaining the change.
Repeated Upward Revision of Injectable Lines Target · 14 May 2026. Across all three consecutive calls, management increased the stated total injectable lines target without any explanation. The figure rose from 12 lines in Nov 2025, to 14-15 lines in Feb 2026, to 17 lines in May 2026 - a 42% increase over six months - while the stated completion window also widened from two years to two to three years. Investors modeling the US capacity buildout and revenue ramp have no stable anchor as the target has shifted materially with each call.
Capex Completion Timeline Extended Without Explanation · 14 May 2026. In the Feb 2026 call, the CFO stated the remaining approximately 615 crores of the 1,000 crore capex plan would be spent within the next 12 to 18 months, implying completion by mid-to-late 2027. In the May 2026 call, the remaining balance of approximately 510 crores is now guided to take 18 to 24 months, pushing implied completion to late 2027 or mid-2028. The implied spending rate slowed materially across the two calls with no explanation provided, directly delaying when new capacity becomes operational and revenue-generating.
🚨 Receivables Days Commitment Missed and Target Quietly Expanded · 14 May 2026. In the Feb 2026 call, the CFO explicitly committed to returning receivables days to the stated 120-day benchmark by March 2026, or at latest June 2026. The May 2026 call reveals Q4 FY26 receivables at 136 days, or 125 days after adjusting for FCTR - both figures above the committed level by a meaningful margin. More significantly, management has now widened the stated acceptable range to 130 days going forward without acknowledging the prior commitment was missed, effectively shifting the benchmark post-facto.
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Kwality Pharmaceuticals Ltd539997 | 73.7/100Favorable setup82% evidence | LEADER | 31.1/35 Revenue 37.9% · PAT 88.4% · OPM change 3 pp 95% evidence | 17.8/25 ROCE 24.1% · OPM 25% 76% evidence | 6.2/20 P/E 46.3× · PEG — 50% evidence | 18.6/20 RS sector 72.7% · RS bench 113.3% · 1Y 288.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.1 + 17.8 + 6.2 + 18.6 = 73.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Glenmark Pharmaceuticals LtdGLENMARK | 71.1/100Favorable setup100% evidence | TURNING | 30.8/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 18.2/25 ROCE 39.8% · OPM 20% 100% evidence | 12.4/20 P/E 21.9× · PEG 1.43 100% evidence | 9.7/20 RS sector -11.1% · RS bench 15.2% · 1Y 17.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 18.2 + 12.4 + 9.7 = 71.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Bliss GVS Pharma LtdBLISSGVS | 69.5/100Favorable setup82% evidence | LEADER | 29.0/35 Revenue 20.6% · PAT 25.7% · OPM change 7 pp 95% evidence | 14.8/25 ROCE 16.9% · OPM 27% 76% evidence | 6.0/20 P/E 55.7× · PEG — 50% evidence | 19.7/20 RS sector 102.4% · RS bench 147.9% · 1Y 362.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 14.8 + 6 + 19.7 = 69.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Ipca Laboratories LtdIPCALAB | 67.9/100Favorable setup82% evidence | BREAKING OUT | 26.3/35 Revenue 10.6% · PAT 68% · OPM change 6 pp 95% evidence | 15.8/25 ROCE 17% · OPM 24% 76% evidence | 11.0/20 P/E 36.4× · PEG — 50% evidence | 14.8/20 RS sector -0.6% · RS bench 28.3% · 1Y 47.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 15.8 + 11 + 14.8 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Lupin LtdLUPIN | 66.8/100Favorable setup93% evidence | ASLEEP | 29.6/35 Revenue 28.2% · PAT 49.2% · OPM change 2 pp 100% evidence | 19.3/25 ROCE 29.9% · OPM 30% 100% evidence | 16.3/20 P/E 16.1× · PEG 0.54 65% evidence | 1.6/20 RS sector -26.2% · RS bench -4% · 1Y 7.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29.6 + 19.3 + 16.3 + 1.6 = 66.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26.2% and the one-year return is 7.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Emcure Pharmaceuticals LtdEMCURE | 66.3/100Favorable setup75% evidence | LEADER | 27.3/35 Revenue 18.4% · PAT 32.2% · OPM change 1 pp 95% evidence | 18.2/25 ROCE 24% · OPM 21% 76% evidence | 9.9/20 P/E 36.4× · PEG — 15% evidence | 10.9/20 RS sector -2.5% · RS bench 25.5% · 1Y 44.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 27.3 + 18.2 + 9.9 + 10.9 = 66.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Corona Remedies LtdCORONA | 65.2/100Favorable setup73% evidence | BREAKING OUT | 23.0/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 20.4/25 ROCE 33.3% · OPM 22% 100% evidence | 11.8/20 P/E 64.4× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 23 + 20.4 + 11.8 + 10 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Fredun Pharmaceuticals LtdFREDUN | 64.9/100Mixed-positive evidence74% evidence | 26.7/35 Revenue 91.5% · PAT 100% · OPM change 0 pp 95% evidence | 13.0/25 ROCE 21.3% · OPM 14% 95% evidence | 9.3/20 P/E 53.3× · PEG — 15% evidence | 15.9/20 RS sector 24.1% · RS bench 96.2% · 1Y 9.2%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 26.7 + 13 + 9.3 + 15.9 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Accent Microcell LtdACCENTMIC | 64.5/100Mixed-positive evidence63% evidence | LEADER | 17.5/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 18.9/25 ROCE 24.9% · OPM 16% 95% evidence | 8.7/20 P/E 39.7× · PEG — 50% evidence | 19.4/20 RS sector 44.8% · RS bench 83.4% · 1Y 160.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 18.9 + 8.7 + 19.4 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Caplin Point Laboratories Ltdthis pageCAPLIPOINT | 61.8/100Mixed-positive evidence100% evidence | LEADER | 19.0/35 Revenue 15% · PAT 19.6% · OPM change 0 pp 100% evidence | 17.7/25 ROCE 24.2% · OPM 35% 100% evidence | 9.4/20 P/E 31.5× · PEG 1.52 100% evidence | 15.7/20 RS sector 5.8% · RS bench 36.1% · 1Y 28.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 17.7 + 9.4 + 15.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Rubicon Research LtdRUBICON | 57.6/100Mixed-positive evidence73% evidence | BREAKING OUT | 24.1/35 Revenue 46.8% · PAT 91.4% · OPM change 2 pp 100% evidence | 17.9/25 ROCE 28.4% · OPM 24% 100% evidence | 5.6/20 P/E 105× · PEG 2.63 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 24.1 + 17.9 + 5.6 + 10 = 57.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Marksans Pharma LtdMARKSANS | 57.4/100Mixed-positive evidence87% evidence | BREAKING OUT | 25.8/35 Revenue 19.6% · PAT 48% · OPM change 9 pp 100% evidence | 15.8/25 ROCE 18.8% · OPM 25% 100% evidence | 6.3/20 P/E 28.9× · PEG 2.85 65% evidence | 9.5/20 RS sector -18.1% · RS bench 58.3% · 1Y 95%11 of 11 weeks ahead 70% evidence |
| Exact sum: 25.8 + 15.8 + 6.3 + 9.5 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Ajanta Pharma LtdAJANTPHARM | 56.3/100Mixed-positive evidence100% evidence | BREAKING OUT | 21.3/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 19.6/25 ROCE 34.5% · OPM 26% 100% evidence | 5.5/20 P/E 38.9× · PEG 2.31 100% evidence | 9.9/20 RS sector -5.3% · RS bench 22.1% · 1Y 35.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 19.6 + 5.5 + 9.9 = 56.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Strides Pharma Science LtdSTAR | 55.9/100Mixed-positive evidence75% evidence | TURNING | 20.6/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 13.3/25 ROCE 18.3% · OPM 18% 76% evidence | 11.2/20 P/E 18.8× · PEG — 15% evidence | 10.8/20 RS sector -4.1% · RS bench 24% · 1Y 32.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 13.3 + 11.2 + 10.8 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Wockhardt LtdWOCKPHARMA | 54.3/100Mixed-positive evidence74% evidence | TURNING | 24.9/35 Revenue 18.4% · PAT 100% · OPM change 11 pp 74% evidence | 5.3/25 ROCE 7.5% · OPM 21% 100% evidence | 8.8/20 P/E 88.8× · PEG — 15% evidence | 15.3/20 RS sector 10.9% · RS bench 42% · 1Y 47.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 5.3 + 8.8 + 15.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16RPG Life Sciences LtdRPGLIFE | 52.6/100Mixed-positive evidence93% evidence | LEADER | 11.9/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.5/25 ROCE 25.7% · OPM 22% 100% evidence | 11.1/20 P/E 38.2× · PEG 1.43 65% evidence | 12.1/20 RS sector -8.1% · RS bench 19.1% · 1Y 13.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 17.5 + 11.1 + 12.1 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17ERIS Lifesciences LtdERIS | 52.6/100Mixed-positive evidence76% evidence | BASING | 20.4/35 Revenue 9.6% · PAT 62.2% · OPM change -2 pp 95% evidence | 14.3/25 ROCE 14.1% · OPM 34% 76% evidence | 11.9/20 P/E 28.6× · PEG — 50% evidence | 6.0/20 RS sector -13.8% · RS bench -5% · 1Y -21.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 14.3 + 11.9 + 6 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Akums Drugs & Pharmaceuticals LtdAKUMS | 51.3/100Mixed-positive evidence75% evidence | LEADER | 13.2/35 Revenue 9.2% · PAT -15.8% · OPM change 2 pp 95% evidence | 10.9/25 ROCE 14.9% · OPM 15% 76% evidence | 9.6/20 P/E 40× · PEG — 15% evidence | 17.6/20 RS sector 15.9% · RS bench 48% · 1Y 68.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 10.9 + 9.6 + 17.6 = 51.3 · Decision use: Price leads the evidence: RS versus the benchmark is 48%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Suven Life Sciences LtdSUVEN | 51.0/100Mixed-positive evidence67% evidence | LEADER | 19.8/35 Revenue 25% · PAT -80% · OPM change -997 pp 74% evidence | 2.2/25 ROCE -79.5% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.0/20 RS sector 29.3% · RS bench 63% · 1Y 60%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 2.2 + 10 + 19 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Zydus Lifesciences LtdZYDUSLIFE | 49.3/100Mixed-negative evidence100% evidence | FADING | 11.9/35 Revenue 21.1% · PAT -2.5% · OPM change -8 pp 100% evidence | 16.7/25 ROCE 21.1% · OPM 24% 100% evidence | 13.7/20 P/E 22.9× · PEG 1.23 100% evidence | 7.0/20 RS sector -11.7% · RS bench 14.3% · 1Y 10.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 16.7 + 13.7 + 7 = 49.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 21J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 47.1/100Mixed-negative evidence96% evidence | 10.6/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 20.6/25 ROCE 25.4% · OPM 22% 100% evidence | 3.9/20 P/E 53.8× · PEG 2.34 100% evidence | 12.0/20 RS sector -0.3% · RS bench 23.5% · 1Y 40.2%3 of 4 weeks ahead to 2026-07-19 100% evidence | |
| Exact sum: 10.6 + 20.6 + 3.9 + 12 = 47.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 22Lincoln Pharmaceuticals LtdLINCOLN | 46.8/100Mixed-negative evidence87% evidence | ASLEEP | 15.1/35 Revenue 10% · PAT 11.5% · OPM change 0 pp 95% evidence | 15.3/25 ROCE 16.3% · OPM 15% 95% evidence | 10.8/20 P/E 13× · PEG — 50% evidence | 5.6/20 RS sector -15.1% · RS bench 9.9% · 1Y 11.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 15.3 + 10.8 + 5.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Alkem Laboratories LtdALKEM | 45.1/100Mixed-negative evidence82% evidence | ASLEEP | 14.6/35 Revenue 13.4% · PAT -5.5% · OPM change -2 pp 95% evidence | 17.4/25 ROCE 21.2% · OPM 20% 76% evidence | 11.6/20 P/E 26.8× · PEG — 50% evidence | 1.5/20 RS sector -28.5% · RS bench -6.5% · 1Y -4.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 17.4 + 11.6 + 1.5 = 45.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Aurobindo Pharma LtdAUROPHARMA | 44.8/100Mixed-negative evidence100% evidence | LEADER | 16.5/35 Revenue 9.1% · PAT 9.5% · OPM change 1 pp 100% evidence | 12.3/25 ROCE 12.9% · OPM 21% 100% evidence | 4.8/20 P/E 25.6× · PEG 2.67 100% evidence | 11.2/20 RS sector -1.3% · RS bench 26.9% · 1Y 60.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 12.3 + 4.8 + 11.2 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Sun Pharmaceutical Industries LtdSUNPHARMA | 44.2/100Mixed-negative evidence100% evidence | TURNING | 16.9/35 Revenue 11.4% · PAT 16.5% · OPM change -2 pp 100% evidence | 17.3/25 ROCE 20.5% · OPM 29% 100% evidence | 4.3/20 P/E 35× · PEG 3.8 100% evidence | 5.7/20 RS sector -19.4% · RS bench 4.7% · 1Y 15.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 17.3 + 4.3 + 5.7 = 44.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 26Kilitch Drugs (India) LtdKILITCH | 44.1/100Mixed-negative evidence87% evidence | FADING | 13.9/35 Revenue 14% · PAT 9.3% · OPM change -1 pp 95% evidence | 9.2/25 ROCE 13.4% · OPM 6.5% 95% evidence | 14.2/20 P/E 21.6× · PEG — 50% evidence | 6.8/20 RS sector -15.6% · RS bench 10% · 1Y 0.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 9.2 + 14.2 + 6.8 = 44.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 27Gufic BioSciences LtdGUFICBIO | 44.0/100Mixed-negative evidence94% evidence | BREAKING OUT | 23.1/35 Revenue 16.6% · PAT 17.7% · OPM change 3 pp 100% evidence | 9.8/25 ROCE 12.3% · OPM 18% 100% evidence | 2.3/20 P/E 58× · PEG 4.78 100% evidence | 8.8/20 RS sector -18.4% · RS bench 26.1% · 1Y 19.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 23.1 + 9.8 + 2.3 + 8.8 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Alembic Pharmaceuticals LtdAPLLTD | 43.7/100Mixed-negative evidence94% evidence | BREAKING OUT | 16.4/35 Revenue 14.1% · PAT 14.6% · OPM change -1 pp 100% evidence | 8.4/25 ROCE 12.6% · OPM 15% 100% evidence | 12.5/20 P/E 21.4× · PEG 1.74 100% evidence | 6.4/20 RS sector -24.1% · RS bench 1.5% · 1Y -14.3%4 of 11 weeks ahead 70% evidence |
| Exact sum: 16.4 + 8.4 + 12.5 + 6.4 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Amrutanjan Health Care LtdAMRUTANJAN | 43.2/100Mixed-negative evidence87% evidence | BASING | 13.2/35 Revenue 10.7% · PAT -1.1% · OPM change -2.9 pp 95% evidence | 14.9/25 ROCE 24.8% · OPM 6.1% 95% evidence | 14.3/20 P/E 22.8× · PEG — 50% evidence | 0.8/20 RS sector -37.2% · RS bench -17% · 1Y -36.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 14.9 + 14.3 + 0.8 = 43.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 30Mankind Pharma LtdMANKIND | 42.9/100Mixed-negative evidence100% evidence | BASING | 16.8/35 Revenue 14.2% · PAT 8% · OPM change 2 pp 100% evidence | 13.8/25 ROCE 13.5% · OPM 26% 100% evidence | 8.2/20 P/E 44.2× · PEG 2.81 100% evidence | 4.1/20 RS sector -22.9% · RS bench 0.4% · 1Y -10.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 13.8 + 8.2 + 4.1 = 42.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31FDC LtdFDC | 41.9/100Mixed-negative evidence94% evidence | ASLEEP | 12.8/35 Revenue 3.5% · PAT 8.2% · OPM change -1 pp 100% evidence | 12.9/25 ROCE 15.4% · OPM 21% 100% evidence | 11.9/20 P/E 18× · PEG 2 100% evidence | 4.3/20 RS sector -25.1% · RS bench -11.7% · 1Y -27.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.8 + 12.9 + 11.9 + 4.3 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Indoco Remedies LtdINDOCO | 40.7/100Thin evidence · provisional58% evidence | TURNING | 20.2/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.4/25 ROCE 1% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.1/20 RS sector -32.2% · RS bench 14.2% · 1Y -3.8%7 of 10 weeks ahead 70% evidence |
| Exact sum: 20.2 + 4.4 + 10 + 6.1 = 40.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Zim Laboratories LtdZIMLAB | 39.9/100Mixed-negative evidence79% evidence | LEADER | 9.6/35 Revenue 7.5% · PAT -60.6% · OPM change -3.3 pp 71% evidence | 6.1/25 ROCE 4.8% · OPM 2.6% 95% evidence | 5.8/20 P/E 202× · PEG — 50% evidence | 18.4/20 RS sector 25.7% · RS bench 59.5% · 1Y 87.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9.6 + 6.1 + 5.8 + 18.4 = 39.9 · Decision use: Price leads the evidence: RS versus the benchmark is 59.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 34Torrent Pharmaceuticals LtdTORNTPHARM | 39.8/100Mixed-negative evidence100% evidence | BREAKING OUT | 16.6/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 14.2/25 ROCE 15.2% · OPM 34% 100% evidence | 0.8/20 P/E 84.6× · PEG 5.11 100% evidence | 8.2/20 RS sector -7.4% · RS bench 19.5% · 1Y 39%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 14.2 + 0.8 + 8.2 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Bafna Pharmaceuticals LtdBAFNAPH | 39.8/100Mixed-negative evidence60% evidence | TURNING | 11.5/35 Revenue -3.1% · PAT -5.8% · OPM change -11.3 pp 95% evidence | 7.3/25 ROCE 11.9% · OPM 3.4% 76% evidence | 8.7/20 P/E 91.5× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 84.4% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 11.5 + 7.3 + 8.7 + 12.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Bajaj Healthcare LtdBAJAJHCARE | 37.8/100Mixed-negative evidence87% evidence | BREAKING OUT | 9.8/35 Revenue 12.3% · PAT -59.1% · OPM change 1 pp 95% evidence | 10.3/25 ROCE 11.5% · OPM 17% 95% evidence | 11.9/20 P/E 20× · PEG — 50% evidence | 5.8/20 RS sector -29.8% · RS bench -7.1% · 1Y -22.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 10.3 + 11.9 + 5.8 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Natco Pharma LtdNATCOPHARM | 37.3/100Mixed-negative evidence100% evidence | ASLEEP | 3.0/35 Revenue -20.8% · PAT -32.5% · OPM change -18 pp 100% evidence | 14.1/25 ROCE 17.4% · OPM 25% 100% evidence | 19.1/20 P/E 12.8× · PEG 0.76 100% evidence | 1.1/20 RS sector -31.6% · RS bench -10.9% · 1Y -4.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 3 + 14.1 + 19.1 + 1.1 = 37.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 38Biocon LtdBIOCON | 36.2/100Mixed-negative evidence100% evidence | ASLEEP | 13.3/35 Revenue 9.8% · PAT -36.4% · OPM change 1 pp 100% evidence | 7.7/25 ROCE 3.6% · OPM 20% 100% evidence | 11.5/20 P/E 87.5× · PEG 0.82 100% evidence | 3.7/20 RS sector -22.1% · RS bench 1.3% · 1Y 7.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 7.7 + 11.5 + 3.7 = 36.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Bharat Parenterals LtdBPLPHARMA | 35.8/100Thin evidence · provisional58% evidence | 12.3/35 Revenue -11.2% · PAT 16% · OPM change -2.8 pp 71% evidence | 4.1/25 ROCE -1.9% · OPM 9.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.4/20 RS sector -12.8% · RS bench 24.2% · 1Y 10.6%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 12.3 + 4.1 + 10 + 9.4 = 35.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 40Cipla LtdCIPLA | 32.6/100Adverse evidence100% evidence | BASING | 4.6/35 Revenue 1.8% · PAT -37.7% · OPM change -9 pp 100% evidence | 12.3/25 ROCE 15.5% · OPM 17% 100% evidence | 12.0/20 P/E 30.8× · PEG 1.25 100% evidence | 3.7/20 RS sector -25.3% · RS bench -2.3% · 1Y -12.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 4.6 + 12.3 + 12 + 3.7 = 32.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Dr Reddys Laboratories LtdDRREDDY | 30.1/100Adverse evidence100% evidence | BASING | 3.7/35 Revenue -0.9% · PAT -44.6% · OPM change -14 pp 100% evidence | 11.7/25 ROCE 13% · OPM 11% 100% evidence | 13.3/20 P/E 30.2× · PEG 1.15 100% evidence | 1.4/20 RS sector -28% · RS bench -5.9% · 1Y -8.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 3.7 + 11.7 + 13.3 + 1.4 = 30.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 42Influx Healthtech LtdINFLUX | 59.8/100Thin evidence · provisional50% evidence | TURNING | 19.3/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 20.8/25 ROCE 40% · OPM 19% 95% evidence | 10.3/20 P/E 30.5× · PEG — 15% evidence | 9.4/20 RS sector -9.8% · RS bench 16% · 1Y 43.4%10 of 12 weeks ahead 70% evidence |
| Exact sum: 19.3 + 20.8 + 10.3 + 9.4 = 59.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Syncom Healthcare LtdSYNCOM | 49.7/100Thin evidence · provisional31% evidence | 17.1/35 Revenue -69.4% · PAT 63.5% · OPM change — 16% evidence | 6.9/25 ROCE -20.2% · OPM -225.7% 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.7/20 RS sector 29.1% · RS bench 45.7% · 1Y —9 of 12 weeks ahead to 2021-06-30 70% evidence | |
| Exact sum: 17.1 + 6.9 + 10 + 15.7 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44Sai Parenterals LtdSAIPARENT | 37.4/100Thin evidence · provisional38% evidence | ASLEEP | 13.7/35 Revenue — · PAT — · OPM change -1 pp 32% evidence | 5.1/25 ROCE 5.3% · OPM 13.2% 95% evidence | 8.6/20 P/E 111× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 9 weeks ahead 0% evidence |
| Exact sum: 13.7 + 5.1 + 8.6 + 10 = 37.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Caplin Point Laboratories Ltd's share price today?
Caplin Point Laboratories Ltd trades at ₹2,755, +22.7% over the past year. The company is valued at ₹20,940 Cr. The stock sits at 96% of its 52-week range of ₹1,558–₹2,811, +24.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 14 weeks in. — as of 11 September 2026.
What were Caplin Point Laboratories Ltd's latest quarterly results?
Caplin Point Laboratories Ltd reported revenue of ₹610 Cr and net profit of ₹179 Cr for the Jun 26 quarter. Revenue rose 19.6% and profit rose 18.5% year on year. Earnings per share were ₹23.27. The operating margin was 35.0%, 0.0 pp higher than a year earlier. — as of 11 September 2026.
What is Caplin Point Laboratories Ltd's revenue?
Caplin Point Laboratories Ltd reported revenue of ₹610 Cr in the Jun 26 quarter, +19.6% year on year. For the full FY26 fiscal year, revenue was ₹2,187 Cr (+12.9%). Over the last 10 years revenue compounded at 24.8% a year. — as of 11 September 2026.
What is Caplin Point Laboratories Ltd's profit?
Caplin Point Laboratories Ltd earned ₹179 Cr of net profit in the Jun 26 quarter, +18.5% year on year — the 12th straight quarter of growth. Full-year FY26 profit was ₹650 Cr. The operating margin ran 35.0% in the latest quarter. — as of 11 September 2026.
What is Caplin Point Laboratories Ltd's market cap?
Caplin Point Laboratories Ltd's market capitalisation is ₹20,940 Cr at a share price of ₹2,755. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Caplin Point Laboratories Ltd's P/E ratio?
Caplin Point Laboratories Ltd trades at a P/E of 31.5×, at the 83rd percentile of its own 11-year range, against a long-run median of 22.4×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Caplin Point Laboratories Ltd pay a dividend?
Yes — Caplin Point Laboratories Ltd's dividend payout was 9% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Caplin Point Laboratories Ltd overvalued?
On its own history, Caplin Point Laboratories Ltd looks expensive: its P/E of 31.5× sits at the 83rd percentile of its 11-year range (long-run median 22.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Caplin Point Laboratories Ltd growing?
Yes — Caplin Point Laboratories Ltd is growing: latest-quarter revenue +19.6% year on year, profit +18.5%, and the margin +0.0 pp at 35.0%. The 10-year compound rates are 24.8% (revenue) and 30.3% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Caplin Point Laboratories Ltd performing?
Caplin Point Laboratories Ltd is in a confirmed uptrend, 14 weeks in. Its latest quarter's revenue rose 19.6% and profit rose 18.5% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 25 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Caplin Point Laboratories Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 24.4% and holding. The read comes from the last 12 quarters of growth (revenue growth +15.0% latest, profit growth +19.6% latest, eps growth +17.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Caplin Point Laboratories Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 14 of stage 2), trading +24.2% versus its 200-day average and at 96% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Caplin Point Laboratories Ltd beating the market?
On recent form, yes — Caplin Point Laboratories Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 25 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +1,242% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Caplin Point Laboratories Ltd's share price go up?
This page publishes no price forecast for Caplin Point Laboratories Ltd. What it measures instead: the share price is ₹2,755, the price is in a confirmed uptrend 14 weeks in. Its P/E of 31.5× sits at the 83rd percentile of its own 11-year range. — as of 11 September 2026.
Who owns Caplin Point Laboratories Ltd?
Promoters hold 70.6% of Caplin Point Laboratories Ltd, foreign institutions 5.8%, domestic institutions 2.5% and the public 21.2% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 2.4 points over 8 quarters. — as of 11 September 2026.
Does Caplin Point Laboratories Ltd have too much debt?
No — Caplin Point Laboratories Ltd's debt-to-equity is 0.07, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹221 Cr against equity of ₹3,370 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Caplin Point Laboratories Ltd's capex?
Caplin Point Laboratories Ltd spent ₹505 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹197 Cr, with ₹234 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Caplin Point Laboratories Ltd's cash flow?
Caplin Point Laboratories Ltd generated ₹523 Cr of operating cash flow in FY26 and ₹326 Cr of free cash flow after ₹197 Cr of capital spending. Reported profit that year was ₹650 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Caplin Point Laboratories Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 77% of Caplin Point Laboratories Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹523 Cr against reported profit of ₹650 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.
Where is Caplin Point Laboratories Ltd in its business cycle?
Caplin Point Laboratories Ltd's FY26 operating margin was 35.0%, against a 13-year band of 21.0%–36.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 35.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Caplin Point Laboratories Ltd's price assume?
At its price on 24 August 2026, Caplin Point Laboratories Ltd was priced for profit growth of about 16.6% a year. Profit itself has compounded 30.3% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Caplin Point Laboratories Ltd story?
The sharpest disagreement: the engine is strong, but at the 83rd percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Caplin Point Laboratories Ltd a stock worth studying right now?
This is not investment advice. The machine read: Caplin Point Laboratories Ltd is strength at full price. The numbers are improving — and a P/E at the 83rd percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!